Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Schedule 1 - Sterling Green Group Plc

14 May 2012 07:30

RNS Number : 2506D
AIM
14 May 2012
 



ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR COMPANIES ("AIM RULES")

COMPANY NAME:

 

STERLING GREEN GROUP PLC TO BE RENAMED FASTNET OIL & GAS PLC (THE "COMPANY")

 

COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TRADING ADDRESS (INCLUDING POSTCODES) :

REGISTERED OFFICE AND TRADING ADDRESS

Number 14, The Embankment

Vale Road

Heaton Mersey

Stockport,

Cheshire SK4 3GN

United Kingdom

 

TRADING ADDRESS

18 Fitzwilliam Place,

Dublin 2,

Ireland

 

COUNTRY OF INCORPORATION:

 

England and Wales

 

COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE 26:

 

http://sterlinggreen.co.uk/sgg/ to become www.fastnetoilandgas.com following admission

 

COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING POLICY). IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED:

 

The Company has, since 1 December 2011, been classified as an investing company under Rule 15 of the AIM Rules for Companies ("AIM Rules"). On 14 May 2012 the Company entered into a conditional agreement to acquire the entire issued share capital of Terra Energy Limited ("Terra") for an aggregate consideration to be satisfied by the issue of 64,129,611 consideration shares and the payment of €40,000. The acquisition constitutes a reverse takeover under Rule 14 of the AIM Rules. The Company is also proposing to raise £10.0 million (before expenses) through a conditional placing of 90,909,091 new ordinary shares (following the share consolidation) to provide further working capital for the enlarged group.

 

Terra was incorporated in February 2008 and was established to explore and develop unconventional oil and gas resources in Europe and North Africa. Terra has since focused on oil and gas prospects in the Celtic Sea. In addition, Terra plans to avail itself of new potential opportunities in North and East Africa where certain of the proposed directors have significant knowledge, contacts.

 

On Admission, Terra's assets will include an interest in a net profit bonus arrangement relating to the Connemara prospects offshore Ireland ("NPB Agreement") and 13 coal licenses based in the Connaught Coal Field, onshore Ireland. Terra has also made applications to the Petroleum Affairs Division of the Department of Communications, Energy and Natural Resources of Ireland for three offshore licensing options in the Celtic Sea and an onshore licence in the Dublin Basin.

 

DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER OF THE SECURITIES (i.e. where known, number and type of shares, nominal value and issue price to which it seeks admission and the number and type to be held as treasury shares):

 

163,030,160 ordinary shares of 3.8p each ("Ordinary Shares")

 

CAPITAL TO BE RAISED ON ADMISSION (IF APPLICABLE) AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION:

 

Placing of 90,909,091 Ordinary Shares at 11p per Ordinary Share to raise £10.0 million

 

Approximate market capitalisation of £17.93 million on Admission at the placing price

 

PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION:

 

25.85%

 

DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM COMPANY HAS APPLIED OR AGREED TO HAVE ANY OF ITS SECURITIES (INCLUDING ITS AIM SECURITIES) ADMITTED OR TRADED:

 

The Enterprise Securities Market, a market regulated by the Irish Stock Exchange

 

FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the first name by which each is known or including any other name by which each is known):

 

Cathal Martin Friel Non-Executive Chairman

 

George Henry Stephen Staley CEO

 

Michael Henry Nolan Non-Executive Director

 

John Michael Edelson Non-Executive Director

 

FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER ADMISSION (underlining the first name by which each is known or including any other name by which each is known):

 

Currently

On Admission

Name

Number of Ordinary Shares held

Percentage of issued share capital

Number of Ordinary Shares held

Percentage of issued share capital

Cathal Friel 1

0

0

18,888,051

11.59%

Henderson Global Investors Limited

0

0

8,181,818

5.02%

CQS Asset Management Limited

0

0

7,500,000

4.60%

Davycrest Nominees

0

0

7,136,363

4.38%

Mandatum Life Insurance Company Limited

0

0

6,954,545

4.27%

Standard Life Investments Limited

0

0

6,818,182

4.18%

BlackRock Investment Management (UK) Limited

0

0

5,000,000

3.07%

Michael Edelson2

35,050,390

11.54

922,384

0.57%

Selwyn Lewis

29,687,500

9.78

781,250

0.48%

Rock Nominees Limited

29,687,500

9.78

781,250

0.48%

BK Charitable Trust

15,500,000

5.10

407,894

0.25%

Pentagon Dollar Satellite Fund Limited

15,000,000

4.94

394,736

0.24%

HSBC Global Custody Nominees

15,000,000

4.94

394,736

0.24%

Ian Aspinall3

12,250,000

4.03

322,368

0.20%

Jonathan Lyons

12,000,000

3.95

315,789

0.19%

JIM Nominees Limited

10,308,960

3.39

271,288

0.17%

 

Notes:

1. Cathal Friel's interest in new ordinary shares in the Company will include 15,554,857 new ordinary shares held by Raglan Road Capital Limited, a Company in which Cathal Friel and his wife, Pamela Iyer, have a 90 per cent. interest.

2. Michael Edelson's interest in existing ordinary shares in the Company include 1,000,000 shares held by his wife, JB Edelson, 1,750,000 shares held by Novabank Capital Limited and 3,800,390 shares held by London and City Credit Corporation Limited. In addition, Michael Edelson holds 1,000,000 existing ordinary shares non-beneficially as a trustee of The Morris Edelson Settlement.

3. Ian Aspinall has non-beneficial interests in existing ordinary shares in the Company, being 8,250,000 shares held non-beneficially as a trustee of The Blueberry Charitable Trust and 4,000,000 shares held non-beneficially by his wife, J M Aspinall, as a trustee of The Cheshire Children's Charitable Trust.

 

NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES:

 

N/A

 

(i) ANTICIPATED ACCOUNTING REFERENCE DATE

(ii) DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION DOCUMENT HAS BEEN PREPARED (this may be represented by unaudited interim financial information)

(iii) DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS PURSUANT TO AIM RULES 18 AND 19:

 

(i) 31 March;

(ii) 31 March 2012; and

(iii) As follows:

a. 6 months ended 30 September 2012 by 31 December 2012;

b. Year ending 31 March 2013 by 30 September 2013; and

c. 6 months ended 30 September 2013 by 31 December 2013;

 

EXPECTED ADMISSION DATE:

 

11 June 2012

 

NAME AND ADDRESS OF NOMINATED ADVISER:

 

Shore Capital and Corporate Limited

Bond Street House

14 Clifford Street

London W1S 4JU

 

 

NAME AND ADDRESS OF BROKER:

 

Shore Capital Stockbrokers Limited

Bond Street House

14 Clifford Street

London W1S 4JU

 

J & E Davy,

Davy House,

49 Dawson Street,

Dublin 2,

Ireland

 

OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES:

 

Copies of the admission document will be available to the public, free of charge, at the registered office of the Company at Number 14 The Embankment, Vale Road, Heaton Mersey, Stockport SK4 3GN, telephone 0161 975 0434 during normal business hours on any weekday (Saturdays and public holidays excepted) for a period of one month from the date of Admission. This document is also available free of charge for such period on the Company's website at http://sterlinggreen.co.uk/sgg/

 

DATE OF NOTIFICATION:

 

14 May 2012

 

NEW/ UPDATE:

 

NEW

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
PAAAIMATMBIBMJT
Date   Source Headline
6th Jan 20225:30 pmRNSAmryt Pharma
6th Jan 20227:00 amGNWKey Dates for AIM Delisting
4th Jan 202212:00 pmGNWThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
4th Jan 20227:00 amGNWTotal Voting Rights
1st Dec 20217:00 amGNWTotal Voting Rights
30th Nov 20217:00 amGNWDirector/PDMR Shareholding
23rd Nov 202112:00 pmGNWAmryt Provides Update on Regulatory Review Process for Oleogel-S10
22nd Nov 20217:00 amGNWAmryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM
3rd Nov 202111:00 amGNWAmryt Reports Strong Q3 2021 Results
1st Nov 20211:00 pmGNWTotal Voting Rights
1st Nov 20217:00 amRNSAmryt Supports Acromegaly Awareness Day
22nd Oct 20217:00 amRNSAmryt Supports Global EB Awareness Week 2021
20th Oct 202112:00 pmGNWAmryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3
19th Oct 202112:00 pmGNWAmryt Announces New Patents for Oleogel-S10 and Mycapssa®
23rd Sep 202112:00 pmRNSAmryt Supports Global FH Awareness Day
13th Sep 202112:00 pmGNWAmryt Raises Full Year 2021 Revenue Guidance to $220M - $225M
1st Sep 20217:00 amGNWTotal Voting Rights
19th Aug 20217:00 amGNWAmryt Issues Ordinary Shares and Total Voting Rights
13th Aug 20211:23 pmRNSHolding(s) in Company - Replacement
11th Aug 202111:30 amRNSHoldings in Company
11th Aug 202110:36 amRNSHolding(s) in Company
10th Aug 20212:20 pmGNWDirector/PDMR Shareholding
10th Aug 20219:53 amRNSHolding(s) in Company
9th Aug 202112:00 pmGNWAmryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
6th Aug 202112:00 pmGNWAmryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
5th Aug 20213:50 pmGNWAmryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
28th Jul 20213:00 pmGNWResult of General Meetings
12th Jul 202112:00 pmGNWAmryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6
28th Jun 202112:00 pmGNWPublication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
15th Jun 202111:45 amGNWAmryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
7th Jun 202112:00 pmGNWFDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
3rd Jun 20217:00 amGNWFDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
2nd Jun 20211:30 pmGNWAmryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
5th May 20214:41 pmRNSSecond Price Monitoring Extn
5th May 20214:35 pmRNSPrice Monitoring Extension
5th May 202112:05 pmGNWAmryt Reports Record Q1 2021 Financial and Operating Results
5th May 202112:00 pmGNWAmryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
15th Apr 202112:00 pmGNWAmryt to Report Q1 2021 Results and Host Conference Call & Webcast on May 5
6th Apr 20217:00 amGNWAmryt Announces the Appointment of Sheila Frame as President Americas
31st Mar 202111:00 amRNSAmryt Supports World Lipodystrophy Day
31st Mar 20217:00 amGNWAmryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
30th Mar 20217:00 amGNWAmryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS
29th Mar 20217:00 amGNWAmryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)
23rd Mar 20217:00 amGNWAmryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
22nd Mar 20217:00 amGNWAmryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)
15th Mar 202110:00 amGNWDirector/PDMR Shareholding
12th Mar 20217:00 amGNWExercise of Options and Total Voting Rights
11th Mar 202111:30 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
8th Mar 20216:00 pmGNWDirector/PDMR Shareholding
8th Mar 20217:00 amGNWAmryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.